Table 28

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

Characteristics

Total (n = 452)

CMV viremia (n = 181)

P value

CMV disease

(n = 32)

P value

Age, median years (range)

57 (18–77)

56 (18–77)

0.286

55 (25–74)

0.724

Male, n (%)

277 (61.3%)

105 (37.9%)

0.243

19 (6.9%)

0.818

Caucasians, n (%)

381 (84.3%)

134 (35.2%)

<0.001

24 (6.3%)

0.025

HCT-CI ≥3, n (%)

251 (55.5%)

95 (37.8%)

0.287

17 (6.8%)

0.776

Recipient CMV status, n (%)

Negative

185 (40.9%)

7 (3.8%)

<0.001

2 (1.1%)

<0.001

Positive

267 (59.1%)

174 (65.2%)

 

30 (11.2%)

 

Donor CMV status, n (%)

Negative

218 (48.2%)

67 (30.7%)

<0.001

13 (6%)

0.372

Positive

234 (51.8%)

114 (48.7%)

 

19 (8.1%)

 

Letermovira

Yes

176 (65.9%)

113 (64.2%)

0.646

20 (11.4%)

0.927

No

91 (34.1%)

61 (67%)

 

10 (11%)

 

Conditioning, n (%)

Myeloablative

169 (37.4%)

65 (38.5%)

0.596

13 (7.7%)

0.695

Reduced intensity

283 (62.6%)

116 (41%)

 

19 (6.7%)

 

Graft source, n (%)

PBSC

224 (49.6%)

87 (38.8%)

0.604

16 (7.1%)

0.959

Bone marrow

228 (50.4%)

94 (41.2%)

 

16 (7%)

 

GVHD prophylaxis, n (%)

Tac/MTX

241 (53.3%)

92 (38.2%)

0.386

16 (6.6%)

0.696

PT-Cy-based

211 (46.7%)

89 (42.2%)

 

16 (7.6%)

 

Donor type, n (%)

MUD

276 (61.1%)

105 (38%)

0.277

19 (6.9%)

0.839

Haplo

176 (38.9%)

76 (43.2%)

 

13 (7.4%)

 
  1. Total represents column percentages; CMV viremia and disease represent row percentages. KPS Karnofsky performance status, HCT-CI, Hematopoietic cell transplantation-specific comorbidity index, CMV cytomegalovirus, PBSC Peripheral blood stem cells, Tac/MTX Tacrolimus/methotrexate, PT-Cy post-transplant cyclophosphamide, MUD matched unrelated donor, Haplo haploidentical related donor, aLetermovir data is only in CMV seropositive recipients (n  =  267).
Back to article page